Nautilus Biotechnology Inc. $(NAUT)$ reported its financial results for the second quarter of 2025. The company achieved a net loss of $15.0 million, an improvement from the $18.0 million net loss in the same quarter of the previous year. Operating expenses decreased by 18% to $17.1 million, down from $20.8 million in the prior year period, driven by efforts in cost optimization and reduced expenses in salaries, benefits, stock-based compensation, and professional services. Nautilus Biotechnology's cash, cash equivalents, and investments totaled $179.5 million as of June 30, 2025. The company highlighted significant progress in its proteome analysis platform, including sharing a scientific manuscript that introduces and validates their Iterative Mapping method. Additionally, Nautilus announced collaborations with major research institutes to further explore Alzheimer's disease through their platform and Tau proteoform assay.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.